Caspase-1 inhibitor VX-765 alleviates PM2.5-induced hepatic lipid metabolism disorder in mice

Shuai Qin, L. H. Wu, Yongheng Wang, Ning Li, Chuan Qin, Shoufang Jiang, Jing Wei, Ning Wu, Fuyuan Cao, Shuang LiScienceAsia 2025 · DOI

Abstract

Long-term exposure to fine particulate matter (PM$_{2.5}$) is associated with hepatic lipid metabolism disorders, in which caspase-1 is involved. This study investigates the role of the caspase-1 inhibitor VX-765 in mitigating these effects. Using a mouse model of chronic PM$_{2.5}$ exposure, researchers found that VX-765 significantly improves liver health markers and regulates lipid metabolism by modulating key factors such as SREBP-1 and PPAR-$\alpha$. These results suggest that caspase-1 inhibitors offer a novel approach for treating pollution-induced hepatic disorders.

Introduction: The Liver as a Target for Air Pollution

While the respiratory and cardiovascular impacts of PM$_{2.5}$ are well-documented, its effect on the liver—the body's central metabolic hub—is increasingly concerning. PM$_{2.5}$ particles can enter the bloodstream and reach the liver, causing inflammation and "lipid metabolism disorder," an imbalance in fat synthesis and breakdown. This study explores caspase-1, an enzyme central to inflammation and cell death (pyroptosis), as a potential molecular driver of this disorder.

Experimental Methods

The researchers used a controlled animal model to simulate long-term environmental exposure:

  • Exposure Model: Male C57BL/6 mice were exposed to concentrated ambient air particles for 6 hours daily over a 100-day period.
  • Intervention: The caspase-1 inhibitor VX-765 was administered (50 mg/kg every three days) to evaluate its protective effects.
  • Analysis: Researchers monitored serum lipids (TC, TG, HDL, LDL), liver enzymes (AST, ALT), and used molecular techniques (Western Blot, qPCR) to track the expression of metabolic regulators like SREBP-1 and PPAR-$\alpha$.

Key Insights: Caspase-1 as a Metabolic Regulator

The study confirms that caspase-1 acts as a critical metabolic switch under pollution stress. Its activation by PM$_{2.5}$ leads to the upregulation of SREBP-1 (promoting fat synthesis) and the downregulation of PPAR-$\alpha$ (inhibiting fat burning). Chronic exposure also resulted in systemic metabolic strain, evidenced by significant weight loss and an increased liver index.

Importantly, the damage proved reversible. Inhibiting caspase-1 with VX-765 "re-tuned" metabolic gene expression, effectively reducing lipid droplet accumulation and liver stress.

Results: Restoring Lipid Homeostasis and Liver Function

Data from the PM-exposed group showed significant disruption in both liver function and lipid homeostasis compared to healthy controls.

Figure 4: Elevated serum ALT levels in mice exposed to PM2.5, indicating significant liver stress and damage.

As shown in the figures, PM$_{2.5}$ exposure led to a marked increase in liver enzymes like ALT and a rise in serum triglycerides (TG), a hallmark of metabolic disorder.

Figure 5: Significant increase in serum Triglyceride (TG) levels following chronic PM2.5 exposure.

The administration of VX-765 successfully countered these effects. Treated mice showed significantly lower levels of TC, TG, and LDL, and higher levels of "good" cholesterol (HDL) compared to the PM-only group. Histological analysis further confirmed reduced inflammatory infiltration and improved liver tissue architecture.

Conclusion and Future Directions

This research identifies the caspase-1 pathway as a major driver of PM$_{2.5}$-induced liver dysfunction. By demonstrating that the inhibitor VX-765 can alleviate these disorders, the study opens new avenues for therapeutic intervention in populations living in highly polluted areas. Future research will likely explore how this pathway interacts with other metabolic regulators like NF-$\kappa$B and AMPK to provide a more comprehensive understanding of pollution-induced metabolic disease.

Summary updated

Abstract

Long-term exposure to PM 2.5 is associated with hepatic lipid metabolism disorders, in which caspase-1 is involved, but the mechanism is not fully understood.This study focused on the role of the caspase-1 inhibitor VX-765.A long-term PM 2.5 exposure model was constructed by concentrating ambient air particles.Mice were intraperitoneally administered with VX-765.The body weight, liver index, blood lipid, and hepatic disorder indices were measured.Hematoxylin and eosin staining, immunohistochemical staining, Western blot analysis, and real-time quantitative polymerase chain reaction were employed to assess histopathological changes and quantify the expression levels of target proteins and mRNAs.The results indicated that VX-765 could inhibit hepatic disorder, improve body weight and liver index, and regulate lipid metabolism by affecting the expression of key factors such as caspase-1, IL-1, SREBP-1, PPAR-, PPAR-, and PDK4.In conclusion, caspase-1 inhibitors offer a novel approach for alleviating hepatic disorder caused by long-term PM 2.5 exposure.
BibTeX
@inproceedings{qin2025caspase,
  author = {Shuai Qin and L. H. Wu and Yongheng Wang and Ning Li and Chuan Qin and Shoufang Jiang and Jing Wei and Ning Wu and Fuyuan Cao and Shuang Li},
  title = {{Caspase-1 inhibitor VX-765 alleviates PM2.5-induced hepatic lipid metabolism disorder in mice}},
  booktitle = {ScienceAsia},
  year = {2025},
  doi = {10.2306/scienceasia1513-1874.2025.028},
}
Figure